Harrow Health, Inc.
HROW
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of theā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
18 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$42.06
Price+1.01%
$0.42
1Y
Price
Market Cap
$1.568b
Small
Price/Earnings 3y Avg5y Avg
467.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-37.3%
EBITDA Margin-62.4%
Net Profit Margin-20.8%
Free Cash Flow Margin-37.3%
EBITDA Margin-62.4%
Net Profit Margin-20.8%
Free Cash Flow MarginRevenue
$268.675m
-1.3%
1y CAGR+29.5%
3y CAGR+33.8%
5y CAGREarnings
-$14.961m
-191.1%
1y CAGR-30.7%
3y CAGR-41.4%
5y CAGREPS
-$0.40
-185.7%
1y CAGR-26.5%
3y CAGR-31.7%
5y CAGRBook Value
$28.351m
$419.543m
Assets$391.192m
Liabilities$300.668m
DebtDebt to Assets
71.7%
9.6x
Debt to EBITDAFree Cash Flow
$14.278m
-66.6%
1y CAGR+54.2%
3y CAGR-547.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company